A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment With Ropinirole Immediate Release Tablets (REQUIP IR) or Ropinirole Prolonged Release Tablets (SK&F-101468) in Advanced Stage Parkinson's Disease Subjects Who Are Not Adequately Controlled on L-Dopa [levodopa].

Trial Profile

A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment With Ropinirole Immediate Release Tablets (REQUIP IR) or Ropinirole Prolonged Release Tablets (SK&F-101468) in Advanced Stage Parkinson's Disease Subjects Who Are Not Adequately Controlled on L-Dopa [levodopa].

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Ropinirole (Primary)
  • Indications Parkinson's disease; Sleep disorders
  • Focus Therapeutic Use
  • Acronyms PREPARED
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 28 Apr 2009 Sleep outcomes published in abstract format in the proceedings of the 61st Annual Meeting of the American Academy of Neurology.
    • 07 Apr 2009 New source identified and integrated (United Kingdom Clinical Research Network 2480)
    • 26 Aug 2008 Results were presented at the 12th Congress of the European Federation of Neurological Societies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top